Intensive care unit outcomes in elderly cancer patients

Critical Care Clinics

Volumn 19, Issue 4, 2003, Pages 657-675

  Karamlou, Kasra ^a   Nichols, Dane J ^b   Nichols, Craig R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGE; AGED; ARTIFICIAL VENTILATION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; DECISION MAKING; DRUG MEGADOSE; GERIATRICS; HEALTH CARE COST; HEMATOLOGIC MALIGNANCY; HUMAN; INTENSIVE CARE UNIT; MEDICAL SPECIALIST; ONCOLOGY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCORING SYSTEM; SIDE EFFECT; SOLID TUMOR;

EID: 0142250310     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(03)00053-8     Document Type: Review

References (99)

1. Kane RL, Ouslander JG, Abrass IB. Essentials of clinical geriatrics. 4th edition. New York: McGraw-Hill; 1999.
2. Campbell P. Population projections for states by age, sex, race and Hispanic origin: 1995 to 2025. Washington (DC): Bureau of census, Population Division; 1996.
3. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7.
4. Fentiman IS, Tirelli U, Monfardini S, Schneider M, Festen J, Cognetti F, et al. Cancer in the elderly: why so badly treated? Lancet 1990;335:1020-2.
5. Cooper GS, Yuan Z, Landefeld CS, Johanson JF, Rimm AA. A national population-based study of incidence of colorectal cancer and age. Implications for screening in older Americans. Cancer 1995;75:775-81.
6. Clavio M, Casciaro S, Gatti AM, Spriano M, Bonanni F, Poggi A, et al. Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients. Haematologica 1996;81:238-44.
7. Groeger J. Oncology and critical care, preface. Crit Care Clin 2001;17:Xi-Xii.
8. Groeger JS, Lemeshow S, Price K, Nierman DM, White Jr P, Klar J, et al. Multicenter outcome study of cancer patients admitted to the intensive care unit: a probability of mortality model. J Clin Oncol 1998;16:761-70.
9. Staudinger T, Stoiser B, Mullner M, Locker GJ, Laczika K, Knapp S, et al. Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 2000;28:1322-8.
10. Oye RK, Bellamy PE. Patterns of resource consumption in medical intensive care. Chest 1991;99:685-9.
11. Chassin MR. Costs and outcomes of medical intensive care. Med Care 1982;20:165-79.
12. Thibault GE, Mulley AG, Barnett GO, Goldstein RL, Reder VA, Sherman EL, et al. Medical intensive care: indications, interventions, and outcomes. N Engl J Med 1980;302:938-42.
13. Bellamy PE, Oye RK. Admitting elderly patients to the ICU: dilemmas and solutions. Geriatrics 1987;42:61-3, 67-8.
14. McClish DK, Powell SH, Montenegro H, Nochomovitz M. The impact of age on utilization of intensive care resources. J Am Geriatr Soc 1987;35:983-8.
15. McLean RF, McIntosh JD, Kung GY, Leung DM, Byrick RJ. Outcome of respiratory intensive care for the elderly. Crit Care Med 1985;13:625-9.
16. Campion EW, Mulley AG, Goldstein RL, Barnett GO, Thibault GE. Medical intensive care for the elderly. A study of current use, costs, and outcomes. JAMA 1981;246:2052-6.
17. Chalfin DB, Carlon GC. Age and utilization of intensive care unit resources of critically ill cancer patients. Crit Care Med 1990;18:694-8.
18. Hamel MB, Goldman L, Teno J, Lynn J, Davis RB, Harrell Jr FE, et al. Identification of comatose patients at high risk for death or severe disability. SUPPORT Investigators. Understand prognoses and preferences for outcomes and risks of treatments. JAMA 1995;273:1842-8.
19. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998;157:1159-64.
20. Gillespie DJ, Marsh HM, Divertie MB, Meadows 3rd JA. Clinical outcome of respiratory failure in patients requiring prolonged (greater than 24 hours) mechanical ventilation. Chest 1986;90:364-9.
21. Detsky AS, Stricker SC, Mulley AG, Thibault GE. Prognosis, survival, and the expenditure of hospital resources for patients in an intensive-care unit. N Engl J Med 1981;305:667-72.
22. Azoulay E, Recher C, Alberti C, Soufir L, Leleu G, Le Gall JR, et al. Changing use of intensive care for hematological patients: the example of multiple myeloma. Intensive Care Med 1999;25:1395-401.
23. Jackson SR, Tweeddale MG, Barnett MJ, Spinelli JJ, Sutherland HJ, Reece DE, et al. Admission of bone marrow transplant recipients to the intensive care unit: outcome, survival and prognostic factors. Bone Marrow Transplant 1998;21:697-704.
24. Kress JP, Christenson J, Pohlman AS, Linkin DR, Hall JB. Outcomes of critically ill cancer patients in a university hospital setting. Am J Respir Crit Care Med 1999;160:1957-61.
25. Azoulay E, Alberti C, Bornstain C, Leleu G, Moreau D, Recher C, et al. Improved survival in cancer patients requiring mechanical ventilatory support: impact of noninvasive mechanical ventilatory support. Crit Care Med 2001;29:519-25.
26. Patrick W, Webster K, Ludwig L, Roberts D, Wiebe P, Younes M. Noninvasive positive-pressure ventilation in acute respiratory distress without prior chronic respiratory failure. Am J Respir Crit Care Med 1996;153:1005-11.
27. Zimmerman JE, Knaus WA, Wagner DP, Sun X, Hakim RB, Nystrom PO. A comparison of risks and outcomes for patients with organ system failure: 1982-1990. Crit Care Med 1996;24:1633-41.
28. Brivet FG, Kleinknecht DJ, Loirat P, Landais PJ. Acute renal failure in intensive care units-causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. Crit Care Med 1996;24:192-8.
29. Fedullo AJ, Swinburne AJ. Relationship of patient age to cost and survival in a medical ICU. Crit Care Med 1983;11:155-9.
30. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981;9:591-7.
31. Azoulay E, Moreau D, Alberti C, Leleu G, Adrie C, Barboteu M, et al. Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med 2000;26:1817-23.
32. Tumbull AD, Carlon G, Baron R, Sichel W, Young C, Howland W. The inverse relationship between cost and survival in the critically ill cancer patient. Crit Care Med 1979;7:20-3.
33. Schapira DV, Studnicki J, Bradham DD, Wolff P, Jarrett A. Intensive care, survival, and expense of treating critically ill cancer patients. JAMA 1993;269:783-6.
34. Layon AJ, George BE, Hamby B, Gallagher TJ. Do elderly patients overutilize healthcare resources and benefit less from them than younger patients? A study of patients who underwent craniotomy for treatment of neoplasm. Crit Care Med 1995;23:829-34.
35. Studnicki J, Schapira DV, Straumfjord JV, Clark RA, Marshburn J, Werner DC. A national profile of the use of intensive care by Medicare patients with cancer. Cancer 1994;74:2366-73.
36. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
37. Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995;13:2530-9.
38. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
39. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32.
40. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 1985;69:5-11.
41. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol 1997;24:57-69.
42. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997;89:3323-9.
43. Estey EH. How I treat older patients with AML. Blood 2000;96:1670-3.
44. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-54.
45. Estopa R, Torres Marti A, Kastanos N, Rives A, Agusti-Vidal A, Rozman C. Acute respiratory failure in severe hematologic disorders. Crit Care Med 1984;12:26-8.
46. Lloyd-Thomas AR, Dhaliwal HS, Lister TA, Hinds CJ. Intensive therapy for life-threatening medical complications of haematological malignancy. Intensive Care Med 1986;12:317-24.
47. Brunet F, Lanore JJ, Dhainaut JF, Dreyfus F, Vaxelaire JF, Nouira S, et al. Is intensive care justified for patients with haematological malignancies? Intensive Care Med 1990;16:291-7.
48. Storb RF, Champlin R, Riddell SR, Murata M, Bryan S, Warren EH. Non-myeloablative transplants for malignant disease. In: Shechter G, editor. Hematology 2001. Washington (DC): American Society of Hematology; 2001. p. 375-91.
49. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041-50.
50. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-400.
51. Gratwohl A, Passweg J, Baldomero H, Hermans J. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999;24:231-45.
52. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson M, Hickish T, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
53. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
54. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
55. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987;316:1493-8.
56. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290-7.
57. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, et al. Age is not a prognostic variable with autotransplants for multiple myeloma. Blood 1999;93:51-4.
58. Sirohi B, Powles R, Treleaven J, Mainwaring P, Kulkarni S, Pandha H, et al. The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. Bone Marrow Transplant 2000;25:533-9.
59. Torrecilla C, Cortes JL, Chamorro C, Rubio JJ, Galdos P, Dominguez de Villota E. Prognostic assessment of the acute complications of bone marrow transplantation requiring intensive therapy. Intensive Care Med 1988;14:393-8.
60. Denardo SJ, Oye RK, Bellamy PE. Efficacy of intensive care for bone marrow transplant patients with respiratory failure. Crit Care Med 1989;17:4-6.
61. Crawford SW, Petersen FB. Long-term survival from respiratory failure after marrow transplantation for malignancy. Am Rev Respir Dis 1992;145:510-4.
62. Price KJ, Thall PF, Kish SK, Shannon VR, Andersson BS. Prognostic indicators for blood and marrow transplant patients admitted to an intensive care unit. Am J Respir Crit Care Med 1998;158:876-84.
63. Rubenfeld GD, Crawford SW. Withdrawing life support from mechanically ventilated recipients of bone marrow transplants: a case for evidence-based guidelines. Ann Intern Med 1996;125:625-33.
64. Afessa B, Tefferi A, Hoagland HC, Letendre L, Peters SG. Outcome of recipients of bone marrow transplants who require intensive-care unit support. Mayo Clin Proc 1992;67:117-22.
65. Paz HL, Crilley P, Weinar M, Brodsky I. Outcome of patients requiring medical ICU admission following bone marrow transplantation. Chest 1993;104:527-31.
66. Snow RM, Miller WC, Rice DL, Ali MK. Respiratory failure in cancer patients. JAMA 1979;241:2039-42.
67. Epner DE, White P, Krasnoff M, Khanduja S, Kimball KT, Knaus WA. Outcome of mechanical ventilation for adults with hematologic malignancy. J Investig Med 1996;44:254-60.
68. Faber-Langendoen K, Caplan AL, McGlave PB. Survival of adult bone marrow transplant patients receiving mechanical ventilation: a case for restricted use. Bone Marrow Transplant 1993;12:501-7.
69. Peters SG, Meadows 3rd JA, Gracey DR. Outcome of respiratory failure in hematologic malignancy. Chest 1988;94:99-102.
70. Dees A, Ligthart JL, van Putten WL, Planting AS, Stoter G. Mechanical ventilation in cancer patients. Analysis of clinical data and outcome. Neth J Med 1990;37:183-8.
71. Schuster DP, Marion JM. Precedents for meaningful recovery during treatment in a medical intensive care unit. Outcome in patients with hematologic malignancy. Am J Med 1983;75:402-8.
72. Sculier JP. Intensive care in the treatment of cancer patients. Curr Opin Oncol 1991;3:656-62.
73. Ewer MS, Ali MK, Atta MS, Morice RC, Balakrishnan PV. Outcome of lung cancer patients requiring mechanical ventilation for pulmonary failure. JAMA 1986;256:3364-6.
74. Knaus WA, Harrell Jr FE, Lynn J, Goldman L, Phillips RS, Connors Jr AF, et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med 1995;122:191-203.
75. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-8.
76. Hawley PH, Ronco JJ, Guillemi SA, Quieffin J, Russell JA, Lawson LM, et al. Decreasing frequency but worsening mortality of acute respiratory failure secondary to AIDS-related Pneumocystis carinii pneumonia. Chest 1994;106:1456-9.
77. Hook 3rd EW, Horton CA, Schaberg DR. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983;249:1055-7.
78. Conti G, Marino P, Cogliati A, Dell'Utri D, Lappa A, Rosa G, et al. Noninvasive ventilation for the treatment of acute respiratory failure in patients with hematologic malignancies: a pilot study. Intensive Care Med 1998;24:1283-8.
79. Varon J, Walsh GL, Fromm Jr RE. Feasibility of noninvasive mechanical ventilation in the treatment of acute respiratory failure in postoperative cancer patients. J Crit Care 1998;13:55-7.
80. Groeger JS, White Jr P, Nierman DM, Glassman J, Shi W, Horak D, et al. Outcome for cancer patients requiring mechanical ventilation. J Clin Oncol 1999;17:991-7.
81. Bach PB, Schrag D, Nierman DM, Horak D, White Jr P, Young JW, et al. Identification of poor prognostic features among patients requiring mechanical ventilation after hematopoietic stem cell transplantation. Blood 2001;98:3234-40.
82. Kahneman D, Slovic P, Tversky A. Judgment under uncertainty: heuristics and biases. Cambridge (MA): Cambridge University Press; 1987.
83. Huaringa AJ, Leyva FJ, Giralt SA, Blanco J, Signes-Costa J, Velarde H, et al. Outcome of bone marrow transplantation patients requiring mechanical ventilation. Crit Care Med 2000;28:1014-7.
84. Crawford SW, Schwartz DA, Petersen FB, Clark JG. Mechanical ventilation after marrow transplantation. Risk factors and clinical outcome. Am Rev Respir Dis 1988;137:682-7.
85. Shorr AF, Moores LK, Edenfield WJ, Christie RJ, Fitzpatrick TM. Mechanical ventilation in hematopoietic stem cell transplantation: can we effectively predict outcomes? Chest 1999;116:1012-8.
86. Khassawneh BY, White Jr P, Anaissie EJ, Barlogie B, Hiller FC. Outcome from mechanical ventilation after autologous peripheral blood stem cell transplantation. Chest 2002;121:185-8.
87. Nichols DJ, Maziarz RT, Haupt MT. Mechanical ventilation in hematopoietic stem cell transplant patients: is there need for reevaluation? Chest 1999;116:857-9.
88. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
89. Lemeshow S, Teres D, Klar J, Avrunin JS, Gehlbach SH, Rapoport J. Mortality Probability Models (MPM II) based on an international cohort of intensive care unit patients. JAMA 1993;270:2478-86.
90. ESICM/SRLF. Predicting outcome in ICU patients. Second European consensus conference in intensive care medicine 1994;20(5):390-7.
91. Brown MC, Crede WB. Predictive ability of acute physiology and chronic health evaluation II scoring applied to human immunodeficiency virus-positive patients. Crit Care Med 1995;23:848-53.
92. Smith RL, Levine SM, Lewis ML. Prognosis of patients with AIDS requiring intensive care. Chest 1989;96:857-61.
93. Niskanen M, Kari A, Halonen P. Five-year survival after intensive care-comparison of 12,180 patients with the general population. Finnish ICU Study Group. Crit Care Med 1996;24:1962-7.
94. Abbott RR, Setter M, Chan S, Choi K. APACHE II: prediction of outcome of 451 ICU oncology admissions in a community hospital. Ann Oncol 1991;2:571-4.
95. Giangiuliani G, Gui D, Bonatti P, Tozzi P, Caracciolo F. APACHE II in surgical lung carcinoma patients. Chest 1990;98:627-30.
96. Headley J, Theriault R, Smith TL. Independent validation of APACHE II severity of illness score for predicting mortality in patients with breast cancer admitted to the intensive care unit. Cancer 1992;70:497-503.
97. Van Le L, Fakhry S, Walton LA, Moore DH, Fowler WC, Rutledge R. Use of the APACHE II scoring system to determine mortality of gynecologic oncology patients in the intensive care unit. Obstet Gynecol 1995;85:53-6.
98. Boussat S, El'rini T, Dubiez A, Depierre A, Barale F, Capellier G. Predictive factors of death in primary lung cancer patients on admission to the intensive care unit. Intensive Care Med 2000;26:1811-6.
99. Sculier JP, Paesmans M, Markiewicz E, Berghmans T. Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med 2000;28:2786-92.